Universität zu Köln

Shaw, Alice T., Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S. W., Felip, Enriqueta, Chow, Laura Q. M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey ORCID: 0000-0002-2603-7296, Santoro, Armando ORCID: 0000-0003-1709-9492, Lau, Yvonne Y., Goldwasser, Meredith, Boral, Anthony L. and Engelman, Jeffrey A. (2014). Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer. N. Engl. J. Med., 370 (13). S. 1189 - 1198. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Full text not available from this repository.

Abstract

BackgroundNon-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in preclinical studies. MethodsIn this phase 1 study, we administered oral ceritinib in doses of 50 to 750 mg once daily to patients with advanced cancers harboring genetic alterations in ALK. In an expansion phase of the study, patients received the maximum tolerated dose. Patients were assessed to determine the safety, pharmacokinetic properties, and antitumor activity of ceritinib. Tumor biopsies were performed before ceritinib treatment to identify resistance mutations in ALK in a group of patients with NSCLC who had had disease progression during treatment with crizotinib. ResultsA total of 59 patients were enrolled in the dose-escalation phase. The maximum tolerated dose of ceritinib was 750 mg once daily; dose-limiting toxic events included diarrhea, vomiting, dehydration, elevated aminotransferase levels, and hypophosphatemia. This phase was followed by an expansion phase, in which an additional 71 patients were treated, for a total of 130 patients overall. Among 114 patients with NSCLC who received at least 400 mg of ceritinib per day, the overall response rate was 58% (95% confidence interval [CI], 48 to 67). Among 80 patients who had received crizotinib previously, the response rate was 56% (95% CI, 45 to 67). Responses were observed in patients with various resistance mutations in ALK and in patients without detectable mutations. Among patients with NSCLC who received at least 400 mg of ceritinib per day, the median progression-free survival was 7.0 months (95% CI, 5.6 to 9.5). ConclusionsCeritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK. (Funded by Novartis Pharmaceuticals and others; ClinicalTrials.gov number, NCT01283516.) Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in 56% of those who had resistance to crizotinib. Genetic alterations in the anaplastic lymphoma kinase gene (ALK) are implicated in the pathogenesis of several human cancers.(1) ALK can be aberrantly activated by mutation, gene amplification, or chromosomal rearrangement, leading to the expression of a potent oncogenic driver. In non-small-cell lung cancer (NSCLC), ALK rearrangement occurs in approximately 5% of cases.(2)-(8)ALK-rearranged tumors depend on ALK for growth and survival and show marked sensitivity to ALK inhibitors such as crizotinib. Among patients with advanced, ALK-rearranged NSCLC, crizotinib has been associated with response rates of approximately 60% across multiple studies and a median progression-free survival ...

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Shaw, Alice T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kim, Dong-Wan UNSPECIFIED UNSPECIFIED UNSPECIFIED Mehra, Ranee UNSPECIFIED UNSPECIFIED UNSPECIFIED Tan, Daniel S. W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Felip, Enriqueta UNSPECIFIED UNSPECIFIED UNSPECIFIED Chow, Laura Q. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Camidge, D. Ross UNSPECIFIED UNSPECIFIED UNSPECIFIED Vansteenkiste, Johan UNSPECIFIED UNSPECIFIED UNSPECIFIED Sharma, Sunil UNSPECIFIED UNSPECIFIED UNSPECIFIED De Pas, Tommaso UNSPECIFIED UNSPECIFIED UNSPECIFIED Riely, Gregory J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Solomon, Benjamin J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolf, Juergen UNSPECIFIED UNSPECIFIED UNSPECIFIED Thomas, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Schuler, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Liu, Geoffrey UNSPECIFIED orcid.org/0000-0002-2603-7296 UNSPECIFIED Santoro, Armando UNSPECIFIED orcid.org/0000-0003-1709-9492 UNSPECIFIED Lau, Yvonne Y. UNSPECIFIED UNSPECIFIED UNSPECIFIED Goldwasser, Meredith UNSPECIFIED UNSPECIFIED UNSPECIFIED Boral, Anthony L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engelman, Jeffrey A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-443125
DOI:	10.1056/NEJMoa1311107
Journal or Publication Title:	N. Engl. J. Med.
Volume:	370
Number:	13
Page Range:	S. 1189 - 1198
Date:	2014
Publisher:	MASSACHUSETTS MEDICAL SOC
Place of Publication:	WALTHAM
ISSN:	1533-4406
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language EML4-ALK FUSION GENE; KINASE INHIBITOR; ACQUIRED-RESISTANCE; CLINICAL RESISTANCE; MUTATION; EGFR; CRIZOTINIB; GEFITINIB; STI-571; TRIALS Multiple languages Medicine, General & Internal Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/44312